Eribis Pharmaceuticals AB, an Uppsala, Sweden-based developer of novel drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, has received an undisclosed round of financing from Karolinska Development AB.
Based on cardio-protective effects, Eribis’ candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning.
As stated by the company’s CEO, Herman Krapf, the new funds will allow the company to continue its clinical development program.
He said: “We are delighted that Karolinska Development continues to show confidence in our development program.
“This latest round of financing comes after strong preclinical results and means we can now move forward towards the clinical program.
“Successful development offers significant market potential as there is an urgent need for new and improved therapies in the area of cardio-protection”.